CAR T cell therapy for solid tumors: Fatal attraction requires adhesion.

Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors in clinical studies in contrast to hematological malignancies. In a paper recently published in Nature, Larson et al. report that CAR T cell activity against solid tumors depends on cell adhesion mediated by IFNγ signaling, opening the prospect of improving their clinical activity in the future.